ReviewFrontiers in immunology2026
Eosinophils as immunoregulatory players in allergic rhinitis: beyond cytotoxicity.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophils have traditionally been viewed as terminal effector cells in allergic rhinitis (AR), driving tissue damage through the release of cytotoxic granule proteins and pro-inflammatory mediators. However, accumulating evidence over the past two decades has challenged this paradigm, revealing that eosinophils harbor a substantial immunoregulatory repertoire. This Mini Review synthesizes emerging findings on four underappreciated dimensions of eosinophil immunoregulatory function in the context of AR: (i) the capacity of eosinophils to produce interleukin-10 (IL-10) and engage in functional crosstalk with Foxp3+ regulatory T cells (Tregs); (ii) the dual role of eosinophil-derived transforming growth factor-beta (TGF-β) in both tissue remodeling and mucosal tolerance; (iii) eosinophil lipid mediator class-switching from pro-inflammatory cysteinyl leukotrienes (CysLTs) to specialized pro-resolving mediators (SPMs); and (iv) the functional heterogeneity between tissue-resident and inflammatory eosinophil subsets. We further discuss the clinical implications of these findings, including the paradoxical outcomes of anti-IL-5 therapies in AR and the potential of immunoregulatory eosinophil markers as biomarkers for allergen-specific immunotherapy (AIT). A deeper understanding of the context-dependent immunoregulatory functions of eosinophils in the nasal mucosa may inform precision therapeutic strategies that selectively target pro-inflammatory eosinophil subsets while preserving their homeostatic and tolerogenic roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.